Alteplase Linked to Higher Rates of Brain Bleeds
According to researchers, real-world rates of brain bleeds linked to the tissue plasminogen activator (tPA) alteplase (Activase) are much higher than rates recorded in a clinical trial setting.
About the Aleplase Study
Medpage Today reports that a recent study has found that rates of intracerebral hemorrhage linked to Alteplase are nearly double what was recorded in a clinical setting.
In their clinical study, the National Institutes of Neurological Disorders and Stroke (NINDS) recorded a rate of intracerebral hemorrhage of 6.4 percent. Amy Buxton, PA, and her team from Wagner Colege in New York City, however, state that they recorded an intracerebral hemorrhage rate of 15.6 percent.
For their study, Buxton and her colleagues analyzed 173 consecutive patients who were treated for emergent stroke with alteplase between 2006 and 2013 at the emergency department of Staten Island University Hospital.
Of the 173 patients studied, 27 experienced intracerebral bleeds. Further, 11 of the patients who experienced intracerebral bleeds died.
Buxton claims that her study was able to offer a more complete overview of the risk because the study patient selection was not as strict as typically seen in clinical studies.
Side Effects of Altplase
The following adverse events have been observed in patients taking alteplase:
- Pulmonary embolism
- Heart attack
- Brain edema
- Cerebral infarction
- Organ Failure